Back to Search
Start Over
ILB ® Attenuates Clinical Symptoms and Serum Biomarkers of Oxidative/Nitrosative Stress and Mitochondrial Dysfunction in Patients with Amyotrophic Lateral Sclerosis.
- Source :
-
Journal of Personalized Medicine . Aug2021, Vol. 11 Issue 8, p794. 1p. - Publication Year :
- 2021
-
Abstract
- Oxidative/nitrosative stress and mitochondrial dysfunction is a hallmark of amyotrophic lateral sclerosis (ALS), an invariably fatal progressive neurodegenerative disease. Here, as an exploratory arm of a phase II clinical trial (EudraCT Number 2017-005065-47), we used high performance liquid chromatography(HPLC) to investigate changes in the metabolic profiles of serum from ALS patients treated weekly for 4 weeks with a repeated sub-cutaneous dose of 1 mg/kg of a proprietary low molecular weight dextran sulphate, called ILB®. A significant normalization of the serum levels of several key metabolites was observed over the treatment period, including N-acetylaspartate (NAA), oxypurines, biomarkers of oxidative/nitrosative stress and antioxidants. An improved serum metabolic profile was accompanied by significant amelioration of the patients' clinical conditions, indicating a response to ILB® treatment that appears to be mediated by improvement of tissue bioenergetics, decrease of oxidative/nitrosative stress and attenuation of (neuro)inflammatory processes. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20754426
- Volume :
- 11
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- Journal of Personalized Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 152128890
- Full Text :
- https://doi.org/10.3390/jpm11080794